A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naive to Proteasome Inhibitors
Latest Information Update: 24 Aug 2023
At a glance
- Drugs Venetoclax (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms BELLINI
- Sponsors AbbVie
Most Recent Events
- 18 Aug 2023 Time frame changed from Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose to Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group.
- 22 Aug 2022 Status changed from suspended to completed.
- 15 Aug 2022 This trial has been completed in Hungary, according to European Clinical Trials Database.